Hodgkin lymphoma and PD-1 blockade

Reid Merryman, Philippe Armand, Stephen Ansell

Research output: Chapter in Book/Report/Conference proceedingChapter


Classical Hodgkin lymphoma (cHL) is characterized by nearly universal genetic alterations at 9p24.1, resulting in increased expression of PD-1 ligands and immune evasion. Disruption of the PD-1 pathway with anti-PD-1 monoclonal antibodies (mAbs) can restore an antitumor immune response in many patients. Based on high overall response rates in cHL patients with relapsed or refractory (R/R) disease, two PD-1 mAbs, nivolumab and pembrolizumab, received accelerated approval in North America and Europe. Currently, numerous ongoing trials are combining PD-1 mAbs with rationally selected agents in the R/R setting and testing PD-1 blockade earlier in the treatment paradigm with potentially curative therapies. These trials and a rapidly improving understanding of mechanisms of immune resistance to PD-1 blockade have the potential to further improve outcomes for patients with cHL.

Original languageEnglish (US)
Title of host publicationHematologic Malignancies
Number of pages15
StatePublished - 2020

Publication series

NameHematologic Malignancies
ISSN (Print)2197-9766
ISSN (Electronic)2197-9774


  • Immune checkpoint blockade
  • Immune evasion
  • Nivolumab
  • PD-1
  • PD-L1
  • PD-L2
  • Pembrolizumab

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Hodgkin lymphoma and PD-1 blockade'. Together they form a unique fingerprint.

Cite this